Future trials should examine both induction and maintenance therapy applications, biomarker responses, and endoscopic healing outcomes to establish clinical utility
Opting what valid medications to cover based on cost is a dangerous and slippery slope
The patient must: Be age 18 or older Have eligible Medicare Part D coverage Be prescribed treatment specifically for weight reduction and maintenance Participate in ongoing nutrition and physical activity intervention Not have already received a GLP-1 through their Part D plan Not be seeking coverage for another Part D-coverable indication, such as type 2 diabetes, moderate-to-severe obstructive sleep apnea, MASH, or cardiovascular risk reduction The patient must also have met one of these criteria when GLP-1 therapy was originally started: BMI 35 BMI 30 plus HFpEF, uncontrolled hypertension despite 2 medications, or CKD stage 3a+ BMI 27 plus prediabetes, prior MI, prior stroke, or symptomatic peripheral artery disease Important: Eligibility is based on BMI at treatment initiation, not necessarily the patients current BMI
NEWS ALERT Weight Watchers just dropped a major, must-read that reinforces what weve seen firsthand: the WW GLP-1 Success Program works
Retatrutide titration schedule in the combination The retatrutide titration in a combination protocol follows the same fundamental escalation pattern as monotherapy, but with two important modifications
